INNeuStar NYSE NSR UGS and BEA Systems

APT has put together a tremendously talented group ofindividuals, and I look forward to assisting them as they work to improveoutcomes for lung transplant patients." APTs lead product, inhaled cyclosporine, is in Phase III following a Phase IIstudy conducted at the University of Pittsburgh Medical Center, a nationallyrecognized transplant center, and published in the New England Journal ofMedicine in 2006. Patients that received inhaled cyclosporine in addition totheir standard immunosuppressive treatment showed a 78 reduction in mortalitycompared to those in the control group. About APT Pharmaceuticals, Inc.APT Pharmaceuticals, a specialty drug development company primarily focused oninhaled treatments for serious lung diseases, is based in Burlingame,California. Leading life sciences investors including Charter Life Sciences,Great Point Partners, InterWest Partners, Three Arch Partners, Versant Ventures,and Vivo Ventures back APT. Many fans know that NASCAR stands for National Association of Stock Car Auto Racing but some are beginning to wonder if the racing part really fits.This Talladega fall race proved to be a huge disappointment.

NASCAR told drivers there will no longer be bump drafting in the corners. From the start of turn one to the end of turn two no bump drafting, same with three and four.In my opinion and obviously Ryan Newmans, NASCAR took the racing out of racing.Drivers obeyed the no bump drafting rule, surprisingly no one was penalized.Surprised I'm not.Drivers felt the need to show Nascar how wrong they are with the rule change. Without Bump drafting Talladega's not Talladega!Ryan Newman, who's car flipped with five laps to go, expressed his feelings in the no bump drafting rule. Maybe listening to drivers and crews would help.What happened to getting excited about restrictor plate tracks What about theessence of danger and risk What about Real racing . (NASDAQ: NUAN) today announced that Warburg Pincus,the global private equity firm, has agreed to purchase $175 million of Nuancecommon stock, the proceeds of which will be used in conjunction with generalcorporate purposes and potential merger and acquisition activity. Warburg Pincus, a leading investor in technology companies, has agreed topurchase 17,395,626 shares of Nuance common stock at a purchase price of $10.06per share, for an aggregate investment of $175 million. In addition, WarburgPincus will acquire a warrant to purchase 3,862,422 million shares of Nuancecommon stock upon the closing of the investment.

The warrant has an exerciseprice of $11.57 per share and a four-year term. Warburg Pincus has also agreednot to sell any shares of Nuance common stock for a period of six months fromthe closing of the transaction, expected in early February 2009. "Warburg Pincus has enjoyed a long and rewarding relationship with Nuance andwere pleased with the opportunity to invest further in support of the company,"said Pat Hackett, managing director, Warburg Pincus. Please see todays announcement, "Nuance andIBM Establish Agreement to Advance Innovative Speech Solutions."About Warburg PincusWarburg Pincus is a leading global private equity firm. The firm currently hasapproximately $30 billion of assets under management including $10 billionavailable for investment in a range of sectors including healthcare, financialservices, energy, technology, media, telecommunications, consumer, industrialand real estate. Founded in 1966, Warburg Pincus has raised 12private equity funds which have invested more than $29 billion in approximately600 companies in 30 countries. The firm has invested more than $10 billion intechnology, media and telecommunications, including investments in Nuance(NASDAQ: NUAN), Metavante (NSYE: MV), Bharti Tele-ventures (BSE: BHARTI.IN),NeuStar (NYSE: NSR), UGS and BEA Systems.